Valuation: Ultragenyx Pharmaceutical Inc.

Market Cap 2.46B 2.14B 1.99B 1.83B 3.45B 234B 3.51B 23.5B 9.21B 117B 9.23B 9.02B 385B P/E 2026 *
-5.59x
P/E 2027 * -34.9x
Enterprise Value 2.02B 1.76B 1.64B 1.51B 2.84B 193B 2.89B 19.35B 7.58B 96.14B 7.6B 7.43B 317B EV / Sales 2026 *
2.7x
EV / Sales 2027 * 2.03x
Free-Float
96.26%
Yield 2026 *
-
Yield 2027 * -
1 day+2.00%
1 week-6.95%
Current month+0.44%
1 month-25.25%
3 months+1.01%
6 months+0.89%
Current year+8.78%
1 week 24.01
Extreme 24.01
26.15
1 month 24.01
Extreme 24.01
36.57
Current year 18.29
Extreme 18.29
36.57
1 year 18.29
Extreme 18.29
39.89
3 years 18.29
Extreme 18.29
60.37
5 years 18.29
Extreme 18.29
104.38
10 years 18.29
Extreme 18.29
179.65
Manager TitleAgeSince
Chief Executive Officer 65 2010-04-21
Director of Finance/CFO 49 2023-10-15
Chief Tech/Sci/R&D Officer 53 2023-04-30
Director TitleAgeSince
Director/Board Member 65 2010-04-21
Director/Board Member 61 2013-12-31
Director/Board Member 66 2015-02-19
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Chief Financial Officer

-4,698 0.0048%
5/14/26 Free

Director

21,809 0.0222%
3/1/26 Free

Executive/Senior Manager

22,182 0.0230%
Change 5-day change 1-year change 3-year change Capi.($)
+2.00%-6.95%-12.03%-39.42% 2.46B
+1.10%-0.06%-0.19%-85.21% 1.68B
+0.33%-1.30%-11.09%-23.45% 323M
+0.21%-0.21%-52.52% - 53.73M
Average +0.90%-0.17%-18.96%-49.36% 1.13B
Weighted average by Cap. +1.50%-3.51%-8.04%-55.49%

Financials

2026 *2027 *
Net sales 748M 650M 607M 557M 1.05B 71.32B 1.07B 7.16B 2.8B 35.57B 2.81B 2.75B 117B 991M 861M 804M 738M 1.39B 94.42B 1.42B 9.48B 3.71B 47.08B 3.72B 3.64B 155B
Net income -469M -408M -381M -349M -659M -44.71B -670M -4.49B -1.76B -22.3B -1.76B -1.72B -73.55B -82.05M -71.31M -66.58M -61.12M -115M -7.82B -117M -785M -307M -3.9B -308M -301M -12.86B
Net Debt -434M -377M -352M -323M -610M -41.38B -620M -4.15B -1.63B -20.64B -1.63B -1.59B -68.07B -447M -389M -363M -333M -628M -42.65B -639M -4.28B -1.68B -21.27B -1.68B -1.64B -70.16B
Logo Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's clinical-stage pipeline consists of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its products include Crysvita (burosumab), Mepsevii (vestronidase alfa), Dojolvi (triheptanoin), and Evkeeza (evinacumab). Crysvita is used for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Mepsevii is used for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome. Dojolvi is used for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD. Evkeeza is used for the treatment of homozygous familial hypercholesterolemia, or HoFH.
Employees
1,371
Date Price Change Volume
26-08-03 US$25.02 +0.44% 2,085,743
26-07-31 US$24.91 -4.34% 1,537,765
26-07-30 US$26.04 +4.16% 2,675,794
26-07-29 US$25.00 -3.77% 2,330,792
26-07-28 US$25.98 -3.38% 1,844,368
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
25.02USD
Average target price
52.95USD
Spread / Average Target
+111.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RARE Stock